US · Healthcare · Biotechnology
EPS came in at 0.23 against a street estimate of 0.20 — a beat of 15.0%.
Analysts rate Aurinia Pharmaceuticals Inc a buy (5 buy, 2 hold, 0 sell out of 7) with an average price target of $18.00.
| Fund | Stake |
|---|---|
| TANG CAPITAL MANAGEMENT LLC | 9.80% |
| BlackRock Inc | 6.16% |
| The Goldman Sachs Group Inc | 4.22% |
| NEA Management Company, LLC | 2.98% |
| Two Sigma Investments LLC | 2.61% |
| Arrowstreet Capital Limited Partnership | 2.45% |
| State Street Corp | 1.95% |
| Morgan Stanley - Brokerage Accounts | 1.73% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 revenue was $83.699 million, up from $73.468 million in the third quarter of 2025. • Nine-month 2026 revenue w | 2026-10-30 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Q3 2026 total revenue was $83.7 million, up 14% from $73.5 million in Q3 2025. Nine-month revenue was $244.6 million, up 19% from | 2026-10-30 |
| Company announcement · Q3 2026 AURINIA PHARMACEUTICALS INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • No specific financial figures disclosed in this filing • Filing date: August 19, | 2026-08-19 |
| Quarterly report · Q2 2026 AURINIA PHARMACEUTICALS INC. – FORM 10-Q SUMMARY (Q2 2026) HEADLINE NUMBERS • Net product sales (6 months): $152.975 million vs. $126.545 million (2 | 2026-08-06 |
| Results announced · Q3 2026 AURINIA PHARMACEUTICALS INC. — H1 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Total Revenue (6 months): $160.9 million, up 21% from $132.5 million in | 2026-08-06 |
| Shareholder vote results · Q2 2026 AURINIA PHARMACEUTICALS INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Annual shareholder meeting held virtually on June 3, 2026 • Total shares voted: a | 2026-06-04 |
| Acquisition completed · Q2 2026 AURINIA PHARMACEUTICALS INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Acquisition Price: $6.955 per share in cash, plus one contingent value right (CVR | 2026-05-11 |
| Quarterly report · Q1 2026 AURINIA PHARMACEUTICALS INC. – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Net product sales: $73.6 million (Q1 2026) vs. $60.0 million (Q1 2025) — incr | 2026-05-07 |
Readable in the app.
| Announcement | Date |
|---|---|
| Completed acquisition of Kezar Life Sciences for $6.955 per share plus CVR Aurinia Pharmaceuticals completed its acquisition of Kezar Life Sciences on May 11, 2026. Aurinia acquired all outstanding Kezar shares through a tender offer at $6.955 per share in cash plu | 2026-05-11 |
| Agreement and plan of merger with another pharmaceutical company announced Aurinia Pharmaceuticals Inc. has agreed to acquire Kezar Life Sciences, Inc. through a merger agreement dated March 30, 2026. Under the deal structure, Aurinia Pharma U.S., Inc. will merge w | 2026-04-03 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Aurinia Pharmaceuticals Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.